Asset Management One Co. Ltd. Reduces Stock Holdings in Illumina, Inc. $ILMN

Asset Management One Co. Ltd. reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 110,929 shares of the life sciences company’s stock after selling 549 shares during the period. Asset Management One Co. Ltd. owned 0.07% of Illumina worth $10,584,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. 180 Wealth Advisors LLC grew its position in shares of Illumina by 8.4% during the second quarter. 180 Wealth Advisors LLC now owns 35,164 shares of the life sciences company’s stock worth $3,355,000 after acquiring an additional 2,717 shares during the last quarter. Freedom Investment Management Inc. purchased a new position in shares of Illumina during the second quarter worth approximately $301,000. Ethic Inc. grew its position in shares of Illumina by 23.1% during the second quarter. Ethic Inc. now owns 16,678 shares of the life sciences company’s stock worth $1,581,000 after acquiring an additional 3,125 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Illumina by 30.5% during the second quarter. ARK Investment Management LLC now owns 1,168,078 shares of the life sciences company’s stock worth $111,446,000 after acquiring an additional 272,759 shares during the last quarter. Finally, Parcion Private Wealth LLC purchased a new position in shares of Illumina during the second quarter worth approximately $371,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Illumina stock opened at $100.11 on Monday. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The business has a fifty day moving average of $98.17 and a two-hundred day moving average of $91.76. The company has a market cap of $15.39 billion, a P/E ratio of 12.67, a price-to-earnings-growth ratio of 2.47 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the company earned $0.36 earnings per share. Illumina’s quarterly revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ILMN. Citigroup lowered shares of Illumina from a “hold” rating to a “strong sell” rating and lowered their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Daiwa Capital Markets downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a report on Tuesday, August 12th. Stephens set a $110.00 price target on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a report on Saturday. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.